HomeTrialNCT07325136
🔬NCT07325136Phase 1Phase 2RECRUITING

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Study Summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment240 participants
Primary Completion
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.745525+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.